Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization FORT LEE, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...

Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...

Adenoid Cystic Carcinoma Pipeline is Indicative of Many Opportunities Left For Research and Development, Analyzes DelveInsight Las Vegas, USA, March 10, 2022 (GLOBE NEWSWIRE) -- Adenoid Cystic Carcinoma Pipeline is Indicative of Many Opportunities Left For Research and Development, Analyzes DelveInsight Adenoid Cystic...